Description of unilateral kidney embolism and contralateral nephrectomy as a less invasive remnant kidney model in cats; a proof-of-concept study

Abstract

Background: Refined models of kidney disease are critical to better understand disease processes and study novel treatments while minimizing discomfort in research animals. The objective of this study was to report a technique for minimally invasive partial kidney embolism in cats and describe outcomes following transcatheter administration of embolic microspheres with subsequent contralateral nephrectomy.

Methods: Eleven, apparently healthy, male, purpose-bred cats underwent unilateral kidney embolism with 0.25 or 0.5 mL of embolic microparticle (40–120 μm) suspension (0.2 mL microspheres/mL) delivered into the right renal artery under fluoroscopic guidance, followed 5 months later by contralateral nephrectomy. One month after nephrectomy, blood and urinary markers of kidney function were evaluated, and embolized kidneys were harvested for histopathology evaluation.

Results: Renal artery embolization was possible in all cats. Two cats did not complete the study, one after experiencing congestive heart failure (n = 1) and the other following evidence of complete kidney embolism precluding nephrectomy (n = 1) post-embolization. At study end, compared to baseline, cats had significant increases in median (range) serum creatinine (159.1 μmol/L [141.4–530.4] versus 128.2 μmol/L [92.8–150.3]; p = 0.0004), urea nitrogen (15.71 mmol/L [9.29–47.85] versus 7.50 mmol/L [6.07–8.57]; p < 0.0001), and symmetric dimethylarginine (0.74 μmol/L [0.59–3.12] versus 0.67 μmol/L [0.54–0.72]; p = 0.0288) concentrations. No differences in markers of kidney function were documented between dose groups.

Conclusions: Minimally invasive kidney embolism is a promising technique for modeling kidney disease in cats. Understanding optimal dose, timing of nephrectomy, and longer-term consequences requires additional work.

Keywords

chronic kidney disease / experimental model / feline / kidney injury / model / remnant kidney

References

[1] Schmiedt CW, Beita KG, Lourenco BN, et al. A remnant kidney surgery model in cats induces acute and chronic outcomes that mimic spontaneous chronic kidney disease. Am J Vet Res. 2023; 84(8).

[2] Brown SA. Renal pathophysiology: lessons learned from the canine remnant kidney model. J Vet Emerg Crit Care (San Antonio). 2013; 23(2): 115-121.

[3] Brown SA, Brown CA. Single-nephron adaptations to partial renal ablation in cats. Am J Phys. 1995; 269(5 Pt 2): R1002-R1008.

[4] Adam RJ, Williams AC, Kriegel AJ. Comparison of the surgical resection and infarct 5/6 nephrectomy rat models of chronic kidney disease. Am J Physiol Renal Physiol. 2022; 322(6): F639-F654.

[5] Mathur S, Brown CA, Dietrich UM, et al. Evaluation of a technique of inducing hypertensive renal insufficiency in cats. Am J Vet Res. 2004; 65(7): 1006-1013.

[6] Mathur S, Syme H, Brown CA, et al. Effects of the calcium channel antagonist amlodipine in cats with surgically induced hypertensive renal insufficiency. Am J Vet Res. 2002; 63(6): 833-839.

[7] Weng L, Seelig D, Souresrafil O. Long-term implantability of resorbable carboxymethyl cellulose/chitosan microspheres in a rabbit renal arterial embolization model. Cardiovasc Intervent Radiol. 2018; 41(6): 951-958.

[8] van Gelder MK, de Vries JC, Ahmed S, et al. A uremic goat model created by subtotal renal artery embolization and gentamicin. Biology (Basel). 2021; 10(4).

[9] Misra S, Gordon JD, Fu AA, et al. The porcine remnant kidney model of chronic renal insufficiency. J Surg Res. 2006; 135(2): 370-379.

[10] Wang C, Zhang B, Wang H, et al. A feasibility study of using noninvasive renal oxygenation imaging for the early assessment of ischemic acute kidney injury in an embolization model. Magn Reson Imaging. 2019; 63: 178-184.

[11] Acierno MJ, Brown S, Coleman AE, et al. ACVIM consensus statement: guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J Vet Intern Med. 2018; 32(6): 1803-1822.

[12] Schmiedt CW, Mercurio AD, Glassman MM, McAnulty JF, Brown CA, Brown SA. Effects of renal autograft ischemia and reperfusion associated with renal transplantation on arterial blood pressure variables in clinically normal cats. Am J Vet Res. 2009; 70(11): 1426-1432.

[13] Cowgill LD. IRIS guideline recommendations for grading AKI in dogs and cats. Accessed May 28, 2024. http://www.iris-kidney.com/pdf/4_ldc-revised-grading-of-acute-kidney-injury.pdf

[14] Paige CF, Abbott JA, Elvinger F, Pyle RL. Prevalence of cardiomyopathy in apparently healthy cats. J Am Vet Med Assoc. 2009; 234(11): 1398-1403.

[15] Ginat DT, Saad WE, Turba UC. Transcatheter renal artery embolization: clinical applications and techniques. Tech Vasc Interv Radiol. 2009; 12(4): 224-239.

[16] Woodside J, Schwarz H, Bergreen P. Peripheral embolization complicating bilateral renal infarction with gelfoam. AJR Am J Roentgenol. 1976; 126(5): 1033-1034.

[17] Milewski JB, Malewski AW, Malanowska S, et al. Spinal cord damage as a complication of renal artery embolization in patients with renal carcinoma. Int Urol Nephrol. 1981; 13(3): 221-229.

[18] Cox GG, Lee KR, Price HI, Gunter K, Noble MJ, Mebust WK. Colonic infarction following ethanol embolization of renal-cell carcinoma. Radiology. 1982; 145(2): 343-345.

[19] Golab F, Kadkhodaee M, Zahmatkesh M, et al. Ischemic and non-ischemic acute kidney injury cause hepatic damage. Kidney Int. 2009; 75(8): 783-792.

[20] Lourenco BN, Dickerson VM, Brown CA, et al. Development of a model of tubulointerstitial fibrosis using transient unilateral renal ischemia and delayed contralateral nephrectomy in domesticated cats. Comp Med. 2024; 74: 274-283.

[21] Zhang J, Shen R, Lin H, et al. Effects of contralateral nephrectomy timing and ischemic conditions on kidney fibrosis after unilateral kidney ischemia-reperfusion injury. Ren Fail. 2022; 44(1): 1568-1584.

[22] Shiva N, Sharma N, Kulkarni YA, Mulay SR, Gaikwad AB. Renal ischemia/reperfusion injury: an insight on in vitro and in vivo models. Life Sci. 2020; 256: 117860.

[23] De Lombaert MC, Lourenco BN, Coleman AE, Arne AM, Berghaus RD, Schmiedt CW. Effect of gabapentin on ambulatory, direct, systemic arterial blood pressure in apparently healthy cats in the at-home and in-clinic environments. J Feline Med Surg. 2023; 25(8): 1098612X231188770.

[24] Belew AM, Barlett T, Brown SA. Evaluation of the white-coat effect in cats. J Vet Intern Med. 1999; 13(2): 134-142.

[25] Huhtinen M, Derre G, Renoldi HJ, et al. Randomized placebo-controlled clinical trial of a chewable formulation of amlodipine for the treatment of hypertension in client-owned cats. J Vet Intern Med. 2015; 29(3): 786-793.

[26] Glaus TM, Elliott J, Herberich E, Zimmering T, Albrecht B. Efficacy of long-term oral telmisartan treatment in cats with hypertension: results of a prospective European clinical trial. J Vet Intern Med. 2019; 33(2): 413-422.

[27] Coleman AE, Brown SA, Traas AM, Bryson L, Zimmering T, Zimmerman A. Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: results of a double-blind, placebo-controlled, randomized clinical trial. J Vet Intern Med. 2019; 33(2): 478-488.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.